Effects of the 5-HT(2A) receptor antagonist sarpogrelate in diabetic patients with complications. A pilot study

Clinical Drug Investigation

Volumn 18, Issue 3, 1999, Pages 199-207

  Hotta, Nigishi ^a,g   Nakamura, Jiro ^a   Sumita, Yasuhiro ^b   Yasuda, Keigo ^c   Ito, Madoka ^d   Takeuchi, Toshihiko ^e   Hara, Tomohiro ^f   Sakamoto, Nobuo ^f  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NTT Tokai General Hospital   (Japan)

^f CHUBU ROSAI HOSPITAL   (Japan)

^g NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; ORAL ANTIDIABETIC AGENT; SARPOGRELATE; SEROTONIN; SEROTONIN 2A ANTAGONIST;

ADULT; AGED; ANEMIA; ANKLE PRESSURE; ANOREXIA; ARTICLE; CLINICAL TRIAL; COLD; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG HYPERSENSITIVITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR NERVE CONDUCTION; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PARESTHESIA; PERONEUS NERVE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROTONIN BLOOD LEVEL; VIBRATION SENSE;

EID: 0032852582     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199918030-00004     Document Type: Article

References (32)

1. 1. Report of a WHO Study Group. Prevention of diabetes mellitus. WHO Technical Report Series 844. Geneva: WHO, 1994
2. 2. Heistad DD, Harrison DG, Armstrong ML. Serotonin and experimental vascular disease. Int J Cardiol 1987; 14: 205-12
3. 3. Vanhoutte PM. Serotonin, hypertension and vascular disease. Neth J Med 1991; 38: 35-42
4. 4. Villalon CM, Terron JA, Ramirez-San Juan E, et al. 5-Hydroxytryptamine: considerations about discovery, receptor classification and relevance to medical research. Arch Med Res 1995; 26: 331-44
5. 5. Lamping KG. Response of native and stimulated collateral vessels to serotonin. Am J Physiol 1997; 272: H2409-415
6. 6. Barradas MA, Gill DS, Fonseca VA, et al. Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest 1988; 18: 399-404
7. 7. Winocour PH, Klimiuk P, Grennan A, et al. Platelet and plasma vasoactive amines in type 1 (insulin-dependent) diabetes mellitus with and without vascular disease. Ann Clin Biochem 1990; 27: 238-43
8. 8. Hosojima H, Miyauchi E, Morimoto S. Effects of sarpogrelate hydrochloride in patients with peripheral circulatory disorders complicated by diabetic neuropathy. Jpn Pharmacol Ther 1995; 23: 3083-9
9. 9. Kikumoto R, Hara H, Ninomiya K, et al. Syntheses and platelet aggregation inhibitory and antithrombotic properties of [2-[(a)-aminoalkoxy)phenyl]ethyl]benzenes. J Med Chem 1990; 33: 1818-23
10. 10. Hotta N, Sugimura K, Tsuchida I, et al. Use of the C64 quantitative tuning fork and the effect of niceritrol in diabetic neuropathy. Clin Ther 1994; 16: 266-78
11. 11. Yao ST. Haemodynamic studies in peripheral arterial disease. Br J Surg 1970; 57: 761-6
12. 12. Kimura J. Nerve conduction studies. In: Kimura J, editor. Electrodiagnosis in disease of nerve and muscle: principles and practice. 2nd ed. Philadelphia: FA Davis, 1989: 53-162
13. 13. Emson PC, Gilbert RF, Martensson H, et al. Elevated concentration of substance P and 5HT in plasma in patients with carotinoid tumors. Cancer 1984; 54: 715
14. 14. Braune HJ, Geisendorfer H. Measurement of heart rate variations: influencing factors, normal values and diagnostic impact on diabetic autonomic neuropathy. Diabetes Res Clin Pract 1995; 29: 179-87
15. 15. Ludwig C, Schmidt A. Das Verhalten der Gase, welche mit dem Blut durch den veizbaren Säugethiermuskel strömen. Arb Physiol Antalt Leipzig 1868; 3: 1
16. 16. Pietraszek MH, Takada Y, Taminato A, et al. The effect of MCI-9042 on serotonin-induced platelet aggregation in type 2 diabetes mellitus. Thromb Res 1993; 70: 131-8
17. 17. Hara H, Osakabe M, Kitajima A, et al. MCI-9042, a new anti-platelet agent is a selective S2-serotonergic receptor antagonist. Thromb Haemost 1991; 65: 415-20
18. 18. Hara H, Kitajima A, Tamao Y. Improvement of red blood cell deformability by a new anti-platelet agent MCI-9042. Clin Hemorheol 1992; 12: 267-77
19. 19. Yamaguchi H, Furukawa K. Effects of sarpogrelate hydrochloride (MCI-9042) on platelet aggregation, red blood cell deformability and blood viscosity in the treatment of patients with arteriosclerosis obliterans. J ClinTher Med 1991; 7: 1235-41
20. 20. Hara H, Kitajima A, Shimada H, et al. Antithrombotic effect of MCI-9042, a new antiplatelet agent, on experimental thrombosis models. Thromb Haemost 1991; 66: 484-8
21. 21. Furukawa K, Tanabe T, Hoshino S, et al. Therapeutic effects of sarpogrelate hydrochloride (MCI-9042) on chronic arterial occlusive diseases. A double-blind comparison with ticlopidine hydrochloride. J Clin Ther Med 1991; 7: 1747-70
22. 22. Rydel A, Seiffer W. Untersuchungen über das vibrationsgefühl oder die sog, 'Knochensensibilität' (Pallasthesie). Arch Psychiatr Nervenkr 1903; 37: 488-536
23. 23. Thivolet C, el Farkh J, Petiot A, et al. Measuring vibration sensations with graduated tuning fork. Diabetes Care 1990; 13: 1077-80
24. 24. Liniger C, Albeanu A, Bloise D, et al. The tuning fork revisited. Diabetic Med 1990; 7: 859-64
25. 25. Vinik Al, Holland MT, Le Beau JM, et al. Diabetic neuropathics. Diabetes Care 1992; 15: 1926-75
26. 26. Tuck RR, Schmelzer JD, Low PA. Endoncurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. Brain 1984; 107: 935-50
27. 27. Dyck PJ, Hansen S, Karnes J, et al. Capillary number and percentage closed in human diabetic sural nerve. Proc Natl Acad Sci USA 1985; 82: 2513-7
28. 28. Low PA, Tuck RR, Takeuchi M. Nerve microenvironment in diabetic neuropathy. In: Dyck PJ, Thomas PK, Asbury AK, et al, editors. Diabetic neuropathy. Philadelphia: WB Saunders, 1987: 266-78
29. 29. Dyck PJ. Hypoxic neuropathy: does hypoxia play a role in diabetic neuropathy? Neurology 1989; 39: 111-8
30. 30. Hotta N, Kakuta H, Fukasawa H, et al. Effect of niceritrol on streptozotocin-induced diabetic neuropathy in rats. Diabetes 1992; 41: 587-91
31. 31. Hotta N, Koh N, Sakakibara F, et al. Effect of beraprost sodium and insulin on the electroretinogram, nerve conduction, and nerve blood flow in rats with streptozotocin-induced diabetes. Diabetes 1996; 45: 361-6
32. 32. Cameron NE, Colter MA. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 1997; 46 Suppl. 2: S31-7